- Home
- LYEL vs EDD Comparison
LYEL vs EDD Comparison
Compare LYEL & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LYEL | EDD |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | 397.7M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LYEL | EDD |
|---|---|---|
| Price | $19.89 | $5.46 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $27.25 | N/A |
| AVG Volume (30 Days) | 83.6K | ★ 496.0K |
| Earning Date | 03-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.52% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17,438.13 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $4.28 |
| 52 Week High | $45.00 | $6.18 |
Technical Indicators
Market Signals| Indicator | LYEL | EDD |
|---|---|---|
| Relative Strength Index (RSI) | 40.46 | 36.86 |
| Support Level | $15.82 | $5.44 |
| Resistance Level | $27.30 | $5.68 |
| Average True Range (ATR) | 2.18 | 0.09 |
| MACD | -0.29 | -0.01 |
| Stochastic Oscillator | 27.78 | 25.00 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.